Motus GI Holdings, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016166 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.521M	$8.648M	$20.34M
YoY Change	-45.92%	-57.48%	-26.71%
Cash & Equivalents	$8.500M	$8.600M	$20.34M
Short-Term Investments
Other Short-Term Assets	$737.0K	$1.093M	$1.347M
YoY Change	-44.04%	-18.86%	10.41%
Inventory	$823.0K	$798.0K	$700.0K
Prepaid Expenses
Receivables	$106.0K	$52.00K	$18.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$9.810M	$10.26M	$22.40M
YoY Change	-46.08%	-54.22%	-24.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.209M	$1.237M	$2.009M
YoY Change	-9.03%	-38.43%	-1.52%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$13.00K	$13.00K
YoY Change	0.0%	0.0%	30.0%
Total Long-Term Assets	$1.931M	$1.974M	$2.022M
YoY Change	2.22%	-2.37%	-1.84%
TOTAL ASSETS
Total Short-Term Assets	$9.810M	$10.26M	$22.40M
Total Long-Term Assets	$1.931M	$1.974M	$2.022M
Total Assets	$11.74M	$12.23M	$24.43M
YoY Change	-41.53%	-49.92%	-23.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.470M	$1.472M	$1.992M
YoY Change	-33.54%	-26.1%	-1.39%
Accrued Expenses	$243.0K	$248.0K	$296.0K
YoY Change	-8.65%	-16.22%	23.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$2.694M	$2.611M	$1.083M
YoY Change	53.33%	141.09%	-86.43%
Total Short-Term Liabilities	$4.451M	$4.378M	$3.379M
YoY Change	4.66%	29.56%	-67.0%
LONG-TERM LIABILITIES
Long-Term Debt	$3.198M	$3.904M	$10.36M
YoY Change	-45.72%	-62.32%
Other Long-Term Liabilities	$1.135M	$1.128M	$2.077M
YoY Change	-46.03%	-45.69%	-5.59%
Total Long-Term Liabilities	$3.198M	$3.904M	$12.44M
YoY Change	-45.72%	-68.61%	465.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.451M	$4.378M	$3.379M
Total Long-Term Liabilities	$3.198M	$3.904M	$12.44M
Total Liabilities	$12.70M	$13.32M	$15.82M
YoY Change	-21.14%	-15.82%	27.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$148.7M	-$145.7M
YoY Change	12.05%
Common Stock	$1.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$963.0K	-$1.085M	$8.606M
YoY Change
Total Liabilities & Shareholders Equity	$11.74M	$12.23M	$24.43M
YoY Change	-41.53%	-49.92%	-23.36%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001686850
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	mots	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation		usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023Q1	mots	Common Stock Issued For Prepaid Board Of Directors Compensation CommonStockIssuedForPrepaidBoardOfDirectorsCompensation		usd
CY2023Q1	mots	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses		usd
CY2023Q1	mots	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses		usd
CY2023Q1	mots	Financing Fees Included In Accounts Payable And Accrued Expenses FinancingFeesIncludedInAccountsPayableAndAccruedExpenses		usd
CY2023Q1	mots	Prepaid Expenses Resulting From Rightofuse Asset Obtained PrepaidExpensesResultingFromRightofuseAssetObtained		usd
CY2022Q4	mots	Restructuring Liabilities RestructuringLiabilities		usd
CY2023Q1	us-gaap	Restructuring Charges RestructuringCharges		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38389
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Motus GI Holdings, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	81-4042793
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 East Broward Boulevard
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	3rd Floor
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33301
CY2023Q1	dei	City Area Code CityAreaCode	(954)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	541 8000
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	MOTS
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4778873	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8648000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14042000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	52000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	59000	usd
CY2023Q1	mots	Inventory Current InventoryCurrent	464000	usd
CY2022Q4	mots	Inventory Current InventoryCurrent	488000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1093000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	781000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	10257000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15370000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1237000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	334000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	390000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13000	usd
CY2023Q1	us-gaap	Assets Assets	12231000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	9000	usd
CY2022Q4	us-gaap	Assets Assets	17647000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	168000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	182000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	2611000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2532000	usd
CY2023Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1472000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1969000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	248000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	47000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	53000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4378000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4799000	usd
CY2023Q1	mots	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	94000	usd
CY2022Q4	mots	Convertible Debt Unamortized Discount Noncurrent ConvertibleDebtUnamortizedDiscountNoncurrent	108000	usd
CY2023Q1	mots	Convertible Note Noncurrent ConvertibleNoteNoncurrent	3906000	usd
CY2022Q4	mots	Convertible Note Noncurrent ConvertibleNoteNoncurrent	3892000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	104000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Noncurrent DebtInstrumentUnamortizedDiscountNoncurrent	135000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3904000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4589000	usd
CY2023Q1	mots	Contingent Royalty Obligation ContingentRoyaltyObligation	992000	usd
CY2022Q4	mots	Contingent Royalty Obligation ContingentRoyaltyObligation	1212000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	13316000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14670000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	115000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4778873	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4778873	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4659769	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4659769	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144652000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144328000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-145737000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-141351000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1085000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12231000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17647000	usd
CY2023Q1	us-gaap	Revenues Revenues	56000	usd
CY2022Q1	us-gaap	Revenues Revenues	20000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	15000	usd
CY2023Q1	mots	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	165000	usd
CY2022Q1	mots	Costs Of Revenue Impairment Of Inventory CostsOfRevenueImpairmentOfInventory	159000	usd
CY2023Q1	mots	Impairment Of Inventory ImpairmentOfInventory	165000	usd
CY2022Q1	mots	Impairment Of Inventory ImpairmentOfInventory	159000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1454000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1275000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	842000	usd
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	983000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1945000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2114000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	4415000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	4546000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4359000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4526000	usd
CY2023Q1	mots	Loss On Changes In Fair Value Of Contingent Royalty Obligation LossOnChangesInFairValueOfContingentRoyaltyObligation	-220000	usd
CY2022Q1	mots	Loss On Changes In Fair Value Of Contingent Royalty Obligation LossOnChangesInFairValueOfContingentRoyaltyObligation	-29000	usd
CY2023Q1	mots	Finance Income Expense Net FinanceIncomeExpenseNet	239000	usd
CY2022Q1	mots	Finance Income Expense Net FinanceIncomeExpenseNet	332000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-8000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	18000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4811000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.86
CY2023Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	4763210	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	2589712	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2977000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	19000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1085000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9657000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	111000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3005000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	235000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	521000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4811000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8607000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4386000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4811000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	117000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	124000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	62000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	59000	usd
CY2023Q1	mots	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	220000	usd
CY2022Q1	mots	Gain Loss On Change In Estimated Fair Value Of Contingent Royalty Obligation GainLossOnChangeInEstimatedFairValueOfContingentRoyaltyObligation	29000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	222000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	521000	usd
CY2022Q1	mots	Issuance Of Common Stock For Board Of Directors Compensation IssuanceOfCommonStockForBoardOfDirectorsCompensation	57000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	73000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	79000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-91000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	30000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	41000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-22000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	376000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	312000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	378000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-472000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-658000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-74000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-82000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-6000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4802000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5246000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	39000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-39000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3116000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	655000	usd
CY2023Q1	mots	Equity Financing Fees EquityFinancingFees	-19000	usd
CY2022Q1	mots	Equity Financing Fees EquityFinancingFees	-94000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-553000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3022000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5394000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2225000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14042000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22563000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8648000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20338000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	246000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	244000	usd
CY2022Q1	mots	Common Stock Issued For Prepaid Board Of Directors Compensation CommonStockIssuedForPrepaidBoardOfDirectorsCompensation	178000	usd
CY2022Q1	mots	Purchase Of Fixed Assets In Prepaid Expenses PurchaseOfFixedAssetsInPrepaidExpenses	4000	usd
CY2023Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	14000	usd
CY2022Q1	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	12000	usd
CY2022Q1	mots	Purchase Of Property And Equipment In Accounts Payable And Accrued Expenses PurchaseOfPropertyAndEquipmentInAccountsPayableAndAccruedExpenses	45000	usd
CY2022Q1	mots	Financing Fees Included In Accounts Payable And Accrued Expenses FinancingFeesIncludedInAccountsPayableAndAccruedExpenses	17000	usd
CY2023Q1	mots	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation	35000	usd
CY2022Q1	mots	Rightofuse Asset Obtained In Exchange For Lease Obligation RightofuseAssetObtainedInExchangeForLeaseObligation	35000	usd
CY2022Q1	mots	Prepaid Expenses Resulting From Rightofuse Asset Obtained PrepaidExpensesResultingFromRightofuseAssetObtained	3000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	69000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	390000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	428000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	248000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80A_eus-gaap--NatureOfOperations_zv6OsmS2mUSa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_82C_zbpNFMSeIK2f">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motus GI Holdings, Inc. (the “Company”) was incorporated in Delaware, U.S.A. in September 2016. The Company and its subsidiaries, Motus GI Technologies, Ltd. and Motus GI, LLC, are collectively referred to as “Motus GI” or the “Company”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company has developed the Pure-Vu System, a medical device that has been cleared by the U.S. Food and Drug Administration (the “FDA”) to help facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and to help facilitate upper gastrointestinal (“GI”) endoscopy procedures. The Pure-Vu System has received a CE Mark in the EU for use in colonoscopy. The Pure-Vu System integrates with standard and slim colonoscopes, as well as gastroscopes, to improve visualization during colonoscopy and upper GI procedures while preserving established procedural workflow and techniques. Through irrigation and evacuation of debris, the Pure-Vu System is designed to provide better-quality exams. The Company received 510(k) clearance in February 2022 from the FDA for the Pure-Vu EVS System and has commenced commercialization of this product. The Company does not expect to generate significant revenue from product sales until it further expands its commercialization efforts, which is subject to significant uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4400000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4800000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8600000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-145700000	usd
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On July 25, 2022, the Company effected a reverse stock split of its issued and outstanding common stock, par value $0.0001 per share, at a ratio of 1-for-20.
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zATvEnByWB37" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zrcNv2l0b3fl">Use of estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	245000	usd
CY2023Q1	us-gaap	Servicing Liability At Fair Value Description Of Other Changes In Fair Value ServicingLiabilityAtFairValueDescriptionOfOtherChangesInFairValue	The Company recalculated the fair value of the liability by applying a +/- 2% change to the input variable in the discounted cash flow model; the discount rate. A 2% decrease in the discount rate would increase the liability by $94 and a 2% increase in the discount rate would decrease the liability by $84. Such amounts are based on highly sensitive estimates and actual results could result in material change in future periods.
CY2023Q1	mots	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	165000	usd
CY2022Q1	mots	Cost Of Revenue Impairment Of Inventory CostOfRevenueImpairmentOfInventory	159000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	497000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	697000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	164000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	155000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	703000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	548000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	566000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	401000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	798000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	999000	usd
CY2023Q1	mots	Inventory Current InventoryCurrent	464000	usd
CY2022Q4	mots	Inventory Current InventoryCurrent	488000	usd
CY2023Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	334000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	511000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3247000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3218000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2010000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1893000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1237000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1325000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	117000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	124000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	39000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	25000	usd
CY2023Q1	mots	Restructuring Liabilities RestructuringLiabilities	243000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	136000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	178000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	384000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	423000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M14D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0720	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0736	pure
CY2023Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	49000	usd
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	47000	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	246000	usd
CY2022Q1	us-gaap	Interest Expense Other InterestExpenseOther	268000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	62000	usd
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	59000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	308000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	327000	usd
CY2023Q1	us-gaap	Manufacturing Costs ManufacturingCosts	114000	usd
CY2023Q1	us-gaap	Severance Costs1 SeveranceCosts1	1428000	usd
CY2023Q1	mots	License Fees LicenseFees	49000	usd
CY2022Q1	mots	License Fees LicenseFees	47000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	222000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	521000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	26	shares
CY2023Q1	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	the Company commenced a strategic restructuring program aimed at capital preservation. It reduced its quarterly cash expenditures by approximately 35% by eliminating approximately 45% of its workforce during the first quarter of 2023.
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1007000	usd
CY2023Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	1007000	usd

Files In Submission

Name	View Source	Status
mots-20230331_def.xml	Edgar Link	unprocessable
0001493152-23-016166-index-headers.html	Edgar Link	pending
0001493152-23-016166-index.html	Edgar Link	pending
0001493152-23-016166.txt	Edgar Link	pending
0001493152-23-016166-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mots-20230331.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mots-20230331_cal.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
mots-20230331_pre.xml	Edgar Link	unprocessable
mots-20230331_lab.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Motus GI Holdings, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223016166 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission